Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

T De Pas; F de Braud; M Mandalà; G Curigliano; C Catania; G Ferretti; P Sozzi; P Solli; A Goldhirsch

doi:10.1016/s0169-5002(00)00176-8

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

Lung Cancer. 2001 Feb-Mar;31(2-3):267-70. doi: 10.1016/s0169-5002(00)00176-8.

Authors

T De Pas¹, F de Braud, M Mandalà, G Curigliano, C Catania, G Ferretti, P Sozzi, P Solli, A Goldhirsch

Affiliation

¹ Divisions of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy. tommaso.de-pas@ieo.it

PMID: 11165406
DOI: 10.1016/s0169-5002(00)00176-8

Abstract

The aim of the study was to evaluate the activity of cisplatin (CDDP) plus vinorelbine (VNR) in patients with advanced non-small cell lung cancer (NSCLC) progressing after paclitaxel plus gemcitabine. Treatment consisted of CDDP 80 mg/m(2) administered on day 1 and VNR 25 mg/m(2) administered on day 1 and 8, repeated every 3 weeks. Nine patients who relapsed after partial response and eight patients refractory to prior CT received a minimum of two treatment cycles: three patients achieved a PR (18%; 95% CI: 4-43%), four had stable disease and 10 had disease progression. All responses were observed among the nine patients responsive to prior treatment. Median survival was 35 weeks. No patients required dose-reduction, treatment discontinuation or delay because of toxicity. Our results indicate a reasonable antitumor efficacy and no relevant toxicity of a second-line CDDP-based chemotherapy in patients with advanced NSCLC. We recommend the use of this regimen for patients not refractory to primary treatment.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antineoplastic Agents, Phytogenic / administration & dosage*
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Agents, Phytogenic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Cisplatin / administration & dosage*
Cisplatin / adverse effects
Cisplatin / therapeutic use
Deoxycytidine / analogs & derivatives
Deoxycytidine / pharmacology
Disease Progression
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Gemcitabine
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Paclitaxel / pharmacology
Survival Analysis
Vinblastine / administration & dosage*
Vinblastine / adverse effects
Vinblastine / analogs & derivatives*
Vinblastine / therapeutic use
Vinorelbine

Substances

Antineoplastic Agents, Phytogenic
Deoxycytidine
Vinblastine
Paclitaxel
Cisplatin
Vinorelbine
Gemcitabine